Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acrivon Therapeutics, Inc. (ACRV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Acrivon is a clinical stage biopharmaceutical company focused on precision oncology medicines developed using its Generative Phosphoproteomics AP3 platform, and its filings offer additional context on financial results, clinical programs, and business updates.
Among the documents available for ACRV are current reports on Form 8-K, which Acrivon uses to furnish press releases announcing quarterly financial results and to provide Regulation FD disclosures. For example, the company has filed 8-K reports to attach earnings press releases summarizing research and development expenses, cash and investment balances, and narrative business highlights, as well as to furnish a corporate presentation describing AP3 capabilities, synergy data for ACR-368 and ACR-2316 with immune checkpoint inhibitors, and updates to its pipeline overview.
Through this page, users can track how Acrivon reports its progress with lead programs such as ACR-368, a CHK1/CHK2 inhibitor in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, and ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, along with AP3-driven preclinical initiatives. Real-time updates from EDGAR ensure that new ACRV filings, including additional 8-Ks and other periodic reports, are reflected as they become available.
Stock Titan’s interface is designed to pair these filings with AI-powered summaries that explain the key points of each document in clear language. Users can quickly see what each ACRV filing covers—such as financial condition, clinical data highlights, or platform developments—while retaining the ability to open the full SEC text for detailed review, including any exhibits like press releases or corporate presentations incorporated by reference.
Acrivon Therapeutics reported preliminary unaudited cash, cash equivalents and investments of about $119 million as of December 31, 2025, which it currently expects will fund operations into the second quarter of 2027. This extends its financial runway as it advances multiple oncology programs.
The company highlighted updated Phase 2b data for ACR-368 in endometrial cancer, with an overall response rate of 39% in one trial arm and higher confirmed response rates in serous endometrial cancer, guiding a focus on this subgroup and expansion of Arm 3 into the EU with up to 90 subjects. Initial Phase 1 results for ACR-2316 showed tolerability and tumor shrinkage, including a confirmed partial response in endometrial cancer and unconfirmed responses in small cell and squamous non-small cell lung cancers.
Acrivon also nominated ACR-6840, a CDK11 inhibitor, as its next development candidate and outlined milestones through 2026, including Phase 2 updates and Phase 3 readiness for ACR-368, further ACR-2316 data and dose expansion, an IND submission for ACR-6840, and additional AP3-driven programs.
Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.
The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.
After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.
Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.
Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.
Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of
For the nine months ended September 30, net loss was
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of
Acrivon Therapeutics, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025, and business updates. The press release is included as Exhibit 99.1 dated November 13, 2025.
The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings.
Acrivon Therapeutics (ACRV) insider activity: The Chief Legal Officer reported a routine tax-withholding event tied to restricted stock unit vesting. On 10/17/2025, a Form 4 shows transaction code F, where 558 shares of common stock were withheld by the issuer at $1.81 to satisfy mandatory taxes. After this administrative transaction, the officer directly beneficially owns 34,739 shares.